Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene.
Acute megakaryoblastic leukemia (AMKL) in children without Down syndrome (DS) has an extremely poor outcome with 3-year survival of less than 40%, whereas AMKL in children with DS has an excellent survival rate. Recently, a novel recurrent translocation involving CBFA2T3 and GLIS2 was identified in about 30% of children with non-DS AMKL, and the fusion gene was reported as a strong poor prognostic factor in pediatric AMKL. We report the difficult clinical courses of pediatric patients with AMKL harboring the CBFA2T3-GLIS2 fusion gene.
Mayu
M
Ishibashi
Tomoko
T
Yokosuka
Masakatsu D
MD
Yanagimachi
Fuminori
F
Iwasaki
Shin-Ichi
SI
Tsujimoto
Koji
K
Sasaki
Masanobu
M
Takeuchi
Reo
R
Tanoshima
Hiromi
H
Kato
Ryosuke
R
Kajiwara
Fumiko
F
Tanaka
Hiroaki
H
Goto
Shumpei
S
Yokota
D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D059785:Karyotype; D007947:Leukemia, Megakaryoblastic, Acute / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D016896:Treatment Outcome
C577580:CBFA2T3-GLIS2 fusion protein, human; D015514:Oncogene Proteins, Fusion